Reasons to overthrow TURP: bring on Aquablation
- PMID: 32740805
- DOI: 10.1007/s00345-020-03390-x
Reasons to overthrow TURP: bring on Aquablation
Abstract
Purpose: In this review, we will discuss the state of the literature regarding Aquablation, its limitations, and opportunities for its application in the treatment of benign prostatic enlargement (BPE).
Methods: A comprehensive review of original research on Aquablation was conducted. Articles related to transurethral resection of the prostate, holmium laser enucleation of the prostate, greenlight photoselective vaporization of the prostate, and simple prostatectomy were reviewed for discussion.
Results: For small-medium prostates (30-80 mL), Aquablation's main advantages include better ejaculatory function and similar functional outcomes compared to TURP. For large prostates (80-150 mL), Aquablation demonstrates shorter operative time and superior ejaculatory function when compared to simple prostatectomy, HoLEP, and Greenlight PVP. In addition, Aquablation displays shorter hospital stays than simple prostatectomy. The integration of software programming and semi-automatic technology increases the reproducibility of the procedure and helps standardize overall outcomes, while also accelerating the learning curve. Its ability to preserve antegrade ejaculation makes Aquablation a very compelling option for sexually active patients. However cost and postoperative bleeding risks remain a concern.
Conclusion: The current evidence suggests that Aquablation is a safe and effective alternative for BPE for small to large prostates. Further prospective clinical trials, with comparisons to other BPE modalities, and data from longer follow-up periods are still required.
Keywords: Aquablation; BPE; BPH; LUTS; Surgery.
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.
Comment in
-
Benign Prostatic Hyperplasia.J Urol. 2022 Jun;207(6):1323-1325. doi: 10.1097/JU.0000000000002509. Epub 2022 Mar 18. J Urol. 2022. PMID: 35300513 No abstract available.
References
-
- Lokeshwar SD, Harper BT, Webb E et al (2019) Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol 8:529–539. https://doi.org/10.21037/tau.2019.10.01 - DOI - PubMed - PMC
-
- Oelke M, Bachmann A, Descazeaud A et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64:118–140. https://doi.org/10.1016/j.eururo.2013.03.004 - DOI - PubMed
-
- Foster HE, Dahm P, Kohler TS et al (2019) Surgical Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2019. J Urol 202:592–598. https://doi.org/10.1097/JU.0000000000000319 - DOI - PubMed
-
- Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)-incidence, management, and prevention. Eur Urol 50:969–979. https://doi.org/10.1016/j.eururo.2005.12.042 - DOI - PubMed
-
- Pariser JJ, Packiam VT, Adamsky MA, Bales GT (2016) Trends in simple prostatectomy for benign prostatic hyperplasia. Curr Urol Rep 17:57. https://doi.org/10.1007/s11934-016-0610-6 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
